215 related articles for article (PubMed ID: 36697262)
1. Applications and future of aptamers that achieve rapid-onset anticoagulation.
Yu H; Frederiksen J; Sullenger BA
RNA; 2023 Apr; 29(4):455-462. PubMed ID: 36697262
[TBL] [Abstract][Full Text] [Related]
2. Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.
Chabata CV; Frederiksen JW; Olson LB; Naqvi IA; Hall SE; Gunaratne R; Kraft BD; Que LG; Chen L; Sullenger BA
Nucleic Acid Ther; 2022 Jun; 32(3):139-150. PubMed ID: 35021888
[TBL] [Abstract][Full Text] [Related]
3. Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.
Soule EE; Bompiani KM; Woodruff RS; Sullenger BA
Nucleic Acid Ther; 2016 Feb; 26(1):1-9. PubMed ID: 26584417
[TBL] [Abstract][Full Text] [Related]
4. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
Bompiani KM; Monroe DM; Church FC; Sullenger BA
J Thromb Haemost; 2012 May; 10(5):870-80. PubMed ID: 22385910
[TBL] [Abstract][Full Text] [Related]
5. Antidote control of aptamer therapeutics: the road to a safer class of drug agents.
Bompiani KM; Woodruff RS; Becker RC; Nimjee SM; Sullenger BA
Curr Pharm Biotechnol; 2012 Aug; 13(10):1924-34. PubMed ID: 22352726
[TBL] [Abstract][Full Text] [Related]
6. Aptamers: the emerging class of future anticoagulation for vascular disease.
Kuliczkowski W; Floyd J; Malinin A; Serebruany V
Expert Rev Cardiovasc Ther; 2010 Apr; 8(4):503-7. PubMed ID: 20397824
[TBL] [Abstract][Full Text] [Related]
7. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
Nimjee SM; Keys JR; Pitoc GA; Quick G; Rusconi CP; Sullenger BA
Mol Ther; 2006 Sep; 14(3):408-15. PubMed ID: 16765093
[TBL] [Abstract][Full Text] [Related]
8. Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass.
Gunaratne R; Kumar S; Frederiksen JW; Stayrook S; Lohrmann JL; Perry K; Bompiani KM; Chabata CV; Thalji NK; Ho MD; Arepally G; Camire RM; Krishnaswamy S; Sullenger BA
Nat Biotechnol; 2018 Aug; 36(7):606-613. PubMed ID: 29863725
[TBL] [Abstract][Full Text] [Related]
9. An anticoagulant with light-triggered antidote activity.
Heckel A; Buff MC; Raddatz MS; Müller J; Pötzsch B; Mayer G
Angew Chem Int Ed Engl; 2006 Oct; 45(40):6748-50. PubMed ID: 16983715
[No Abstract] [Full Text] [Related]
10. Emerging applications of aptamers for anticoagulation and hemostasis.
Chabata CV; Frederiksen JW; Sullenger BA; Gunaratne R
Curr Opin Hematol; 2018 Sep; 25(5):382-388. PubMed ID: 30015643
[TBL] [Abstract][Full Text] [Related]
11. Antidote-controlled DNA aptamer modulates human factor IXa activity.
Fang L; Jin J; Zhang Z; Yu S; Tian C; Luo F; Long M; Zuo H; Lou S
Bioorg Chem; 2024 Jul; 148():107463. PubMed ID: 38776649
[TBL] [Abstract][Full Text] [Related]
12. Construction of a Bivalent Thrombin Binding Aptamer and Its Antidote with Improved Properties.
Hughes QW; Le BT; Gilmore G; Baker RI; Veedu RN
Molecules; 2017 Oct; 22(10):. PubMed ID: 29048375
[TBL] [Abstract][Full Text] [Related]
13. Development of universal antidotes to control aptamer activity.
Oney S; Lam RT; Bompiani KM; Blake CM; Quick G; Heidel JD; Liu JY; Mack BC; Davis ME; Leong KW; Sullenger BA
Nat Med; 2009 Oct; 15(10):1224-8. PubMed ID: 19801990
[TBL] [Abstract][Full Text] [Related]
14. Selection of an aptamer antidote to the anticoagulant drug bivalirudin.
Martin JA; Parekh P; Kim Y; Morey TE; Sefah K; Gravenstein N; Dennis DM; Tan W
PLoS One; 2013; 8(3):e57341. PubMed ID: 23483901
[TBL] [Abstract][Full Text] [Related]
15. The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome.
Vavalle JP; Cohen MG
Future Cardiol; 2012 May; 8(3):371-82. PubMed ID: 22420328
[TBL] [Abstract][Full Text] [Related]
16. A Protease TAMER: a nucleic acid-based anticoagulant.
Fredenburgh JC; Kretz CA; Weitz JI
J Thromb Haemost; 2012 May; 10(5):867-9. PubMed ID: 22405195
[No Abstract] [Full Text] [Related]
17. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
Tanaka KA; Szlam F; Rusconi CP; Levy JH
Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
[TBL] [Abstract][Full Text] [Related]
18. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
[TBL] [Abstract][Full Text] [Related]
19. Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples.
Soule EE; Yu H; Olson L; Naqvi I; Kumar S; Krishnaswamy S; Sullenger BA
Cell Chem Biol; 2022 Feb; 29(2):215-225.e5. PubMed ID: 35114109
[TBL] [Abstract][Full Text] [Related]
20. [Comparative in vitro study of anticoagulant activity of RA36 DNA aptamer in human, rabbit, and rat blood plasma].
Savchik EIu; Kalinina TB; Drozd NN; Makarov VA; Zav'ialova EG; Lapsheva EN; Babiĭ AV; Mudrik NN; Pavlova GV; Golovin AV; Kopylov AM
Eksp Klin Farmakol; 2012; 75(11):13-8. PubMed ID: 23323327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
